SCHEMBL2295072

SCHEMBL2295072

CSc1ccc(OC(=O)OC(C)OC(=O)C(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.42
AKR1C3 P42330 3/20 0.35
AKR1C2 P52895 3/20 0.35
ACACB O00763 2/20 0.35
MAPT P10636 4/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 2/20 0.35
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.33
RCE1 Q9Y256 1/20 0.33
RAB9A P51151 1/20 0.33
PLK1 P53350 1/20 0.33
MAOB P27338 1/20 0.33
AOC3 Q16853 1/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16702786 0.86 ACACB (0.38) ELANEAKR1C3AKR1C2ACACBMAPT
SCHEMBL2286310 0.85 ELANE (0.41) ELANEAKR1C3AKR1C2ACACBMAPT
SCHEMBL3239401 0.83 ELANE (0.39) ELANEAKR1C3AKR1C2ACACBMAPT
SCHEMBL15967815 0.83 ELANE (0.46) ELANELMNAMEN1KMT2AALDH1A1
SCHEMBL15984582 0.83 LMNA (0.52) ELANEMAPTLMNAMEN1KMT2A
SCHEMBL15967813 0.83 ELANE (0.46) ELANELMNAMEN1KMT2AALDH1A1
SCHEMBL15984566 0.83 LMNA (0.52) ELANEMAPTLMNAMEN1KMT2A
SCHEMBL16003903 0.81 ELANE (0.45) ELANEMAPTLMNANPSR1MEN1
SCHEMBL16003600 0.81 ELANE (0.45) ELANEMAPTLMNANPSR1MEN1
SCHEMBL15967723 0.81 ELANE (0.45) ELANEMAPTKDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516023-B2 NMDA antagonist prodrugs ASTRAZENECA AB (SE) 2026-01-06 US disclosed
EP-4001272-B1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2024-11-13 EP disclosed
EP-4001272-A1 NMDA ANTAGONIST PRODRUGS Astrazeneca AB (SE) 2022-05-25 EP disclosed
EP-3564234-B1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2021-09-29 EP disclosed
US-20210040039-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2021-02-11 US disclosed
US-10815199-B2 NMDA antagonist prodrugs ASTRAZENECA AB (SE) 2020-10-27 US disclosed
CN-111187202-A NMDA antagonist prodrugs 阿斯利康(瑞典)有限公司 2020-05-22 CN disclosed
CN-105683180-B NMDA antagonist prodrugs 阿斯利康(瑞典)有限公司 2020-01-21 CN disclosed
EP-3564234-A1 NMDA ANTAGONIST PRODRUGS AstraZeneca AB (SE) 2019-11-06 EP disclosed
US-20190152914-A1 NMDA ANTAGONIST PRODRUGS ASTRAZENECA AB (SE) 2019-05-23 US disclosed
US-20100087667-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-04-08 US disclosed
US-20100087667-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-04-08 US disclosed
US-20100087667-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-04-08 US disclosed
US-20100081830-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES XENOPORT, INC. (US) 2010-04-01 US disclosed
US-20100081830-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES XENOPORT, INC. (US) 2010-04-01 US disclosed
US-20100081830-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES XENOPORT, INC. (US) 2010-04-01 US disclosed
WO-2010017498-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES XENOPORT, INC. (US) 2010-02-11 WO disclosed
WO-2010017504-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-02-11 WO disclosed
WO-2010017498-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES XENOPORT, INC. (US) 2010-02-11 WO disclosed
WO-2010017504-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS XENOPORT, INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087667-A1 METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS CPS1, ASNS, NAAA ELANE 1960/4885AKR1C3 466/4885AKR1C2 585/4885
US-20210040039-A1 NMDA ANTAGONIST PRODRUGS GRIN1, GRIN2A, GRIN3A ELANE 2956/4885AKR1C3 3604/4885AKR1C2 3547/4885
US-20100081830-A1 METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES CPS1, SI, ASNS ELANE 1609/4885AKR1C3 412/4885AKR1C2 433/4885
US-10815199-B2 NMDA antagonist prodrugs GRIN1, GRIN2A, GRIN3A ELANE 2956/4885AKR1C3 3604/4885AKR1C2 3547/4885
US-20190152914-A1 NMDA ANTAGONIST PRODRUGS GRIN1, GRIN2A, GRIN3A ELANE 2956/4885AKR1C3 3604/4885AKR1C2 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.